Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy

Xiaohong Bi, Brent Rexer, Carlos L. Arteaga, Mingsheng Guo, Anita Mahadevan-Jansen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The overexpression of human epidermal growth factor receptor 2 (HER2) is associated with increased breast cancer recurrence and worse prognosis. Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance. This study applied Raman spectroscopy to differentially identify the amplification status of HER2 in cells and to characterize the biochemical composition of lapatinib resistant and sensitive HER2+ breast cancer cells in response to the drug. Raman spectra from BT474 (HER2+ breast cancer cell), MCF-10A (HER2- control), and HER2+ MCF-10A (HER2+ control) were analyzed using lasso and elastic-net regularized generalized linear models (glmnet) for multivariate statistical analysis and were discriminated to groups of different HER2 expression status with an overall 99% sensitivity and specificity. Enhanced lipid content and decreased proteome were observed in HER2+ cells. With lapatinib treatment, lapatinib-resistant breast cancer cells demonstrated sustained lipogenesis compared with the sensitive cells.

Original languageEnglish (US)
Article number025001
JournalJournal of Biomedical Optics
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2014

Fingerprint

breast
Amplification
Raman spectroscopy
drugs
cancer
Cells
Pharmaceutical Preparations
human ERBB2 protein
Epidermal Growth Factor
cells
proteome
multivariate statistical analysis
prognosis
Proteome
Lipids
lipids
Raman scattering
Statistical methods
Raman spectra
Proteins

Keywords

  • Breast cancer
  • Drug resistance
  • Human epidermal growth factor receptor 2
  • Lapatinib
  • Raman spectroscopy

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Biomaterials
  • Biomedical Engineering

Cite this

Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. / Bi, Xiaohong; Rexer, Brent; Arteaga, Carlos L.; Guo, Mingsheng; Mahadevan-Jansen, Anita.

In: Journal of Biomedical Optics, Vol. 19, No. 2, 025001, 01.02.2014.

Research output: Contribution to journalArticle

@article{fee04b86edbe4c188a1695a33e935fd6,
title = "Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy",
abstract = "The overexpression of human epidermal growth factor receptor 2 (HER2) is associated with increased breast cancer recurrence and worse prognosis. Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance. This study applied Raman spectroscopy to differentially identify the amplification status of HER2 in cells and to characterize the biochemical composition of lapatinib resistant and sensitive HER2+ breast cancer cells in response to the drug. Raman spectra from BT474 (HER2+ breast cancer cell), MCF-10A (HER2- control), and HER2+ MCF-10A (HER2+ control) were analyzed using lasso and elastic-net regularized generalized linear models (glmnet) for multivariate statistical analysis and were discriminated to groups of different HER2 expression status with an overall 99{\%} sensitivity and specificity. Enhanced lipid content and decreased proteome were observed in HER2+ cells. With lapatinib treatment, lapatinib-resistant breast cancer cells demonstrated sustained lipogenesis compared with the sensitive cells.",
keywords = "Breast cancer, Drug resistance, Human epidermal growth factor receptor 2, Lapatinib, Raman spectroscopy",
author = "Xiaohong Bi and Brent Rexer and Arteaga, {Carlos L.} and Mingsheng Guo and Anita Mahadevan-Jansen",
year = "2014",
month = "2",
day = "1",
doi = "10.1117/1.JBO.19.2.025001",
language = "English (US)",
volume = "19",
journal = "Journal of Biomedical Optics",
issn = "1083-3668",
publisher = "SPIE",
number = "2",

}

TY - JOUR

T1 - Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy

AU - Bi, Xiaohong

AU - Rexer, Brent

AU - Arteaga, Carlos L.

AU - Guo, Mingsheng

AU - Mahadevan-Jansen, Anita

PY - 2014/2/1

Y1 - 2014/2/1

N2 - The overexpression of human epidermal growth factor receptor 2 (HER2) is associated with increased breast cancer recurrence and worse prognosis. Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance. This study applied Raman spectroscopy to differentially identify the amplification status of HER2 in cells and to characterize the biochemical composition of lapatinib resistant and sensitive HER2+ breast cancer cells in response to the drug. Raman spectra from BT474 (HER2+ breast cancer cell), MCF-10A (HER2- control), and HER2+ MCF-10A (HER2+ control) were analyzed using lasso and elastic-net regularized generalized linear models (glmnet) for multivariate statistical analysis and were discriminated to groups of different HER2 expression status with an overall 99% sensitivity and specificity. Enhanced lipid content and decreased proteome were observed in HER2+ cells. With lapatinib treatment, lapatinib-resistant breast cancer cells demonstrated sustained lipogenesis compared with the sensitive cells.

AB - The overexpression of human epidermal growth factor receptor 2 (HER2) is associated with increased breast cancer recurrence and worse prognosis. Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance. This study applied Raman spectroscopy to differentially identify the amplification status of HER2 in cells and to characterize the biochemical composition of lapatinib resistant and sensitive HER2+ breast cancer cells in response to the drug. Raman spectra from BT474 (HER2+ breast cancer cell), MCF-10A (HER2- control), and HER2+ MCF-10A (HER2+ control) were analyzed using lasso and elastic-net regularized generalized linear models (glmnet) for multivariate statistical analysis and were discriminated to groups of different HER2 expression status with an overall 99% sensitivity and specificity. Enhanced lipid content and decreased proteome were observed in HER2+ cells. With lapatinib treatment, lapatinib-resistant breast cancer cells demonstrated sustained lipogenesis compared with the sensitive cells.

KW - Breast cancer

KW - Drug resistance

KW - Human epidermal growth factor receptor 2

KW - Lapatinib

KW - Raman spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=84897755948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897755948&partnerID=8YFLogxK

U2 - 10.1117/1.JBO.19.2.025001

DO - 10.1117/1.JBO.19.2.025001

M3 - Article

C2 - 24496495

AN - SCOPUS:84897755948

VL - 19

JO - Journal of Biomedical Optics

JF - Journal of Biomedical Optics

SN - 1083-3668

IS - 2

M1 - 025001

ER -